Group 1 - The core message is that CloudTop New Medicine Co., Ltd. has made progress in patent protection for its innovative drug, Neficon (Budenoside Enteric-Coated Capsules), with a preliminary injunction granted by the Guangzhou Intellectual Property Court [1] - The court's ruling requires related companies to cease the infringing activities and stop product listings, effective immediately [1] - Neficon, approved for market in China in November 2023, is the first and only innovative drug globally for the treatment of IgA nephropathy [1] Group 2 - The patent involved is a Chinese invention patent (Patent No.: ZL200980127272.5), which is currently under effective protection until May 2029 [1] - The industry characteristics of high investment, high risk, and long development cycles are highlighted, emphasizing the importance of a stable and predictable patent protection environment for ongoing innovation [1] - CloudTop New Medicine will continue to legally protect its intellectual property rights and promote innovative therapies for patient benefit [1]
云顶新耀：耐赋康专利诉前保全生效